Omschrijving

I help pharma, biotech, and medtech companies turn complex challenges into clear strategies that unlock growth. As a Harvard-trained MD, ex-BCG consultant, and Principal-level VC investor, I combine scientific depth with strategic and financial expertise.

Clients work with me to assess market opportunities, benchmark competitors, develop go-to-market strategies, or prepare for fundraising and partnerships. My experience spans advising multinationals on R&D transformation and share recovery, leading >€10B in private equity diligences, and supporting early-stage ventures as a board member and investor.

I bring a pragmatic, results-oriented approach that ensures recommendations are not only analytically rigorous but also actionable and aligned with your organization’s goals.

Branche-expertise

Talen

Engels
Tweetalig / moedertaal
Frans
Beperkte professionele capaciteit
Italiaans
Beperkte professionele capaciteit
Nederlands
Beperkte professionele capaciteit
Spaans
Basiskennis

Voorkeuren voor werkplek

Kan op locatie werken

Amsterdam (tot 50km)

Thuja Capital
Principal
PRIVATE EQUITY
januari 2023 - september 2025 (2 jaren en 7 maanden)
Utrecht, Netherlands
Sourced, screened (>300 deals/yr), led diligence, & executed Seed & Series A investments as core part of deal team for Gradient (CVD medtech); Tacalyx (onc biotech); & Brandaris (psych biotech)
Board Observer: Alveron (heme biotech); Pan Cancer T (onc biotech); InnoSIGN (onc medtech); & Atro (ortho medtech), partnering closely with mgmt on (pre)clin dev’l, BD/partnering, & comm strategy
Co-led fund strategy and served on investment committees for Funds II (€35M) & III (€80M), shaping portfolio construction & supporting 9 follow-on rounds from top US & EU VCs, and 1 exit (up to $1B)
Due diligence R&D strategy
Boston Consulting Group
Consultant
CONSULTANCY & AUDITING
augustus 2020 - januari 2023 (2 jaren en 5 maanden)
Amsterdam, Netherlands
Selected projects below:

Led modules on product portfolio analysis & market/competition for 6 buy-side due diligences across healthcare, consumer & industrial sectors, supporting >$10B in total deal value for top-tier PE clients
Advised a global MedTech leader ($5B+ revenue) on strategy to reclaim €100M+ share of EU cardiac device market; identified adoption barriers and optimized commercial levers to accelerate growth
Supported a zero-based budgeting initiative for a global EU PharmaCo ($7B+ revenue), focusing on early R&D; uncovered efficiency levers & reallocation opportunities to optimize innovation investment
Designed and implemented a change & program management system for the vaccines division (£7B+ revenue) of a multinational PharmaCo with a focus on quality and support functions
Due diligence R&D strategy Corporate strategy Commercial strategy
Novartis Venture Fund
MBA Intern
PRIVATE EQUITY
april 2019 - augustus 2019 (4 maanden)
Basel, Switzerland
Analyzed global trends in healthcare VC fundraising, product deals, and exits; synthesized findings to inform strategic direction for senior leadership at a leading global corporate venture capital fund
Benchmarked fund performance of 60+ US/EU life sciences VCs across financial and exit metrics to evaluate market health and identify directional signals to refine investment strategy
Market analysis Corporate strategy